Edwards Lifesciences (NYSE:EW) Hits New 52-Week High – Should You Buy?

Edwards Lifesciences Corporation (NYSE:EW) hit a new 52-week high on Wednesday . The stock traded as high as $90.21 and last traded at $90.44, with a volume of 419047 shares changing hands. The stock had previously closed at $86.95.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Barclays reissued an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Wolfe Research upgraded Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research report on Wednesday, April 1st. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Edwards Lifesciences Trading Up 4.2%

The stock has a market cap of $52.19 billion, a PE ratio of 48.30, a price-to-earnings-growth ratio of 2.15 and a beta of 0.87. The firm has a 50-day moving average price of $83.70 and a 200-day moving average price of $83.16. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the business earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 81,038 shares of company stock valued at $6,683,255 in the last quarter. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently modified their holdings of EW. Hanson & Doremus Investment Management bought a new position in Edwards Lifesciences during the 1st quarter valued at about $25,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences during the third quarter valued at approximately $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences during the fourth quarter valued at approximately $26,000. RMG Wealth Management LLC purchased a new stake in Edwards Lifesciences in the first quarter worth approximately $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter valued at $27,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.